Protocol 3-12

From the Halo Fan Fiction Wikia, writing 12,609 fan fiction articles

Protocol 3-12 is a defined research protocol for mammalian experimentation generated by the Department of Biological Warfare, UNSC Office of Naval Intelligence, developed in collaboration with Acumen Science Laboratories.

[edit] Small-molecule compound timecourse

• Cyclogenol ("AS 163498"): CDKN1B inhibitor

Phenotypical annotation: Giantism and global cellular hyperplasia

Contraindications: Significant increase in tumor occurrence rate by relief of tumor-suppressor mechanisms

• Ossifimorphin ("AS 381506"): ACVR1 agonist

Phenotypical annotation: Heterotopic ossification and substantial osteogenic activity

Contraindications: Ossification of connective tissue

• Myocardin ("AS 974520"): Notch-1 agonist

Phenotypical annotation: Increased cellular proliferation of skeletal muscle and regenerative proliferation after injury

Contraindications: Toxicological properties of myocardin not investigated

• (-)-Bay K 8644: L-type Ca⁺² channel agonist

Phenotypical annotation: Increase in spatial memory (long-term potentiation) and basal metabolic activity (β-cell proliferation)

Contraindications: Increased incidence in pancreatic cancer (insulinoma) incidence

• RO-28-1675: Glucokinase (Gck) agonist

Phenotypical annotation: Increased insulin metabolic kinetics (glucokinase activation) and long-term metabolic stability (reactive β-cell hyperplasia)

Contraindications: Toxicological properties of RO-28-1675 not investigated